DNDN conference call

As I and other investors hoped for, Dendreon CEO Mitch Gold revealed "unambiguous" top-line results that Provenge met the pre-defined primary endpoint for increased survival benefit for late-stage prostate cancer victims in the IMPACT Phase III clinical trial. Shares jumped up over 200% in pre-market open trading. This was a victory for investors and all cancer victims and their families, as other treatments for breast, colorectal, and kidney cancer are also in Dendrean's pipeline. Their cancer immunotherapy platform is a game-changer, and a much better solution than traditional chemotherapy treatments, which carry toxic and adverse side effects.

This paves the way for a New Drug Application (NDA) by the end of 2009, and FDA approval in Q2 2010.